| Community-Based Cognitive Training in Early Schizophrenia (NCT01973270) | University of California, San Francisco | 2013-12-01 |
| A Clinical Trial of Lurasidone in Treatment of Schizophrenia (NCT02002832) | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 2013-12-01 |
| Cognitive Behaviour Therapy for Voices and Dissociation (NCT04990414) | Greater Manchester Mental Health NHS Foundation Trust | 2013-11-24 |
| Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia (NCT01891721) | VA Office of Research and Development | 2013-11-21 |
| Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia (NCT02453893) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2013-11-01 |
| Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode (NCT02267070) | University of California, Los Angeles | 2013-11-01 |
| Early Medication Discontinuation and Long-term Clinical Outcome in FEP (NCT01926340) | Professor Eric Y.H. Chen | 2013-11-01 |
| Glutamate, Learning, and Working Memory (NCT02769936) | University of California, Los Angeles | 2013-11-01 |
| Psychosis-Associated Neuroinflammation in Schizophrenia (NCT02009826) | Universiteit Antwerpen | 2013-11-01 |
| Bioequivalence Fasting Study in Patients (NCT02072954) | Amneal Pharmaceuticals, LLC | 2013-11-01 |
| Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia (NCT02013622) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-11-01 |
| Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia (NCT02202213) | H. Lundbeck A/S | 2013-10-01 |
| Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness (NCT02035202) | University of California, San Diego | 2013-10-01 |
| Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (NCT01994473) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-10-01 |
| Simvastatin Addition for Patients With Recent-onset Schizophrenia (NCT01999309) | Iris Sommer | 2013-10-01 |
| Aripiprazole Once-monthly in Patients With Schizophrenia (NCT01959035) | H. Lundbeck A/S | 2013-10-01 |
| An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia (NCT01939548) | Pfizer | 2013-10-01 |
| Pediatric Open-Label Extension Study (NCT01914393) | Sumitomo Pharma America, Inc. | 2013-09-30 |
| Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations (NCT02149823) | Maria de las Mercedes Perez Rodriguez | 2013-09-01 |
| SCIT Versus TAR for Outpatients With Schizophrenia (NCT03446703) | University of Alcala | 2013-09-01 |
| Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors (NCT02008292) | Yale University | 2013-09-01 |
| Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) (NCT01992393) | Case Western Reserve University | 2013-09-01 |
| Exploration of Neural Bases in Social Cognition (NCT02110017) | University Hospital, Caen | 2013-09-01 |
| Phosphatidylcholine Supplementation in Infants (NCT01905605) | University of Colorado, Denver | 2013-09-01 |
| Remote Cognitive Remediation (NCT02121106) | Queen's University | 2013-09-01 |
| PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia (NCT01854944) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-09-01 |
| Schizophrenia for "Life" - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia (NCT02246283) | Kjeld Andersen | 2013-09-01 |
| A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia (NCT01947803) | Xian-Janssen Pharmaceutical Ltd. | 2013-09-01 |
| Neuroendocrine and Immune Response to Stress in Schizophrenia (NCT01975584) | University of Maryland, Baltimore | 2013-09-01 |
| MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications (NCT01953237) | University of Maryland, Baltimore | 2013-09-01 |
| Effects of Varenicline on Plasticity in Schizophrenia (NCT01934023) | Centre for Addiction and Mental Health | 2013-09-01 |
| Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive (NCT01927276) | University of Maryland, Baltimore | 2013-09-01 |
| Neurobiological Effects of Oxytocin in Schizophrenia - Imaging Study (NCT04158167) | National Institute of Mental Health and Neuro Sciences, India | 2013-09-01 |
| Personalized and Scalable Cognitive Remediation Approaches (NCT01945333) | New York State Psychiatric Institute | 2013-09-01 |
| A PET Study With RO5545965 in Healthy Male Volunteers (NCT01923025) | Hoffmann-La Roche | 2013-08-01 |
| Pediatric Schizophrenia Efficacy and Safety Study (NCT01911429) | Sumitomo Pharma America, Inc. | 2013-08-01 |
| Linagliptin in Schizophrenia Patients (NCT01943019) | Monash University | 2013-08-01 |
| Brief Group Psychoeducation for Schizophrenia (NCT02911519) | Salud Mental Integral S.A.S. | 2013-08-01 |
| A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (NCT01940159) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2013-08-01 |
| Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) (NCT01495741) | Organon and Co | 2013-07-01 |
| Bio-equivalence Study Between SAPHRIS and Asenapine (NCT01948024) | Sun Pharmaceutical Industries Limited | 2013-07-01 |
| An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (NCT01895452) | Alkermes, Inc. | 2013-07-01 |
| Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia (NCT01900522) | Takeda | 2013-07-01 |
| Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana (NCT02593734) | University of Ghana Medical School | 2013-07-01 |
| tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients (NCT01876524) | Spanish Foundation for Neurometrics Development | 2013-07-01 |
| Brexpiprazole in Patients With Schizophrenia (NCT01810783) | H. Lundbeck A/S | 2013-07-01 |
| Safety and Tolerability of BI 409306 in Patients With Schizophrenia (NCT01892384) | Boehringer Ingelheim | 2013-06-28 |
| The Difference of Grey Matter Volume Among the Patients of Schizophrenia (NCT05262790) | Shanghai Mental Health Center | 2013-06-26 |
| A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (NCT01714713) | FORUM Pharmaceuticals Inc | 2013-06-01 |
| Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects (NCT01851603) | University of Colorado, Denver | 2013-06-01 |
| N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia (NCT01885338) | VA Greater Los Angeles Healthcare System | 2013-06-01 |
| Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants (NCT01879722) | Takeda | 2013-06-01 |
| Shared Decision Making for Patients With First-admission Schizophrenia (NCT01869660) | Yokohama City University | 2013-06-01 |
| Factors Influencing Social Functioning of People With Schizophrenia (NCT02166918) | University of Campania Luigi Vanvitelli | 2013-06-01 |
| rTMS for Working Memory Deficits in Schizophrenia (NCT01880255) | Centre for Addiction and Mental Health | 2013-06-01 |
| A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers. (NCT01955564) | Newron Pharmaceuticals SPA | 2013-06-01 |
| Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia (NCT02647437) | University of Colorado, Denver | 2013-06-01 |
| A Study of ALKS 3831 in Adults With Schizophrenia (NCT01903837) | Alkermes, Inc. | 2013-06-01 |
| The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia (NCT01874756) | Indiana University | 2013-06-01 |
| Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (NCT02240446) | University of Minnesota | 2013-06-01 |
| Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia (NCT01850953) | Centre for Addiction and Mental Health | 2013-06-01 |
| Physician Survey on Monitoring of Patients Treated With Quetiapine (NCT01795326) | AstraZeneca | 2013-06-01 |
| Geriatric Psychiatry and Pharmacovigilance (NCT01858857) | Hannover Medical School | 2013-05-01 |
| TDCS for Auditory Hallucinations in Schizophrenia (NCT01898299) | New York State Psychiatric Institute | 2013-05-01 |
| Lurasidone Low-Dose - High-Dose Study Study (NCT01821378) | Sumitomo Pharma America, Inc. | 2013-05-01 |
| Clozapine for Cannabis Use in Schizophrenia (NCT01639872) | Dartmouth-Hitchcock Medical Center | 2013-05-01 |
| Cognitive Remediation in Schizophrenia (NCT01903707) | University of Dublin, Trinity College | 2013-05-01 |
| Effectiveness of Adherence Therapy for Schizophrenia (NCT01780116) | The Hong Kong Polytechnic University | 2013-05-01 |
| A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (NCT01926912) | Janssen-Cilag International NV | 2013-05-01 |
| A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness (NCT01959659) | Hoffmann-La Roche | 2013-05-01 |
| Omega-3 Dietary Supplements in Schizophrenia (NCT01786239) | Delbert Robinson | 2013-05-01 |
| Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (NCT01788774) | Rovi Pharmaceuticals Laboratories | 2013-04-01 |
| Improving Care and Reducing Cost Study (NCT02364544) | Northwell Health | 2013-04-01 |
| Minocycline for Schizophrenia (NCT01809158) | Addis Ababa University | 2013-04-01 |
| Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (NCT01793935) | K.N. Roy Chengappa | 2013-04-01 |
| Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (NCT02011750) | University of Pittsburgh | 2013-04-01 |
| Antipsychotic Effects on Brain Function in Schizophrenia (NCT01913327) | University of California, San Francisco | 2013-04-01 |
| Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic (NCT02007928) | Centre Hospitalier Universitaire de Nice | 2013-04-01 |
| Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning (NCT02901015) | Versailles Hospital | 2013-04-01 |
| Navigated αTMS in Treatment-resistant Schizophrenia (NCT01941251) | Niuvanniemi Hospital | 2013-03-21 |
| A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia (NCT01829048) | Pfizer | 2013-03-06 |
| Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (NCT02055287) | Luye Pharma Group Ltd. | 2013-03-01 |
| Trial of Treatment for Internalized Stigma in Schizophrenia (NCT02421237) | John Jay College of Criminal Justice, City University of New York | 2013-03-01 |
| Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia (NCT01801787) | Charite University, Berlin, Germany | 2013-03-01 |
| Brexpiprazole in Patients With Acute Schizophrenia (NCT01810380) | H. Lundbeck A/S | 2013-03-01 |
| Oxytocin as Adjunctive Treatment of Schizophrenia (NCT01568528) | Emory University | 2013-03-01 |
| Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia (NCT02896374) | Versailles Hospital | 2013-03-01 |
| Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (NCT01834638) | AbbVie | 2013-03-01 |
| Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue (NCT01794429) | Bjorn H. Ebdrup | 2013-02-01 |
| Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (NCT01760993) | Shire | 2013-02-01 |
| Lurasidone Effects on Tissue Glutamate in Schizophrenia (NCT02199743) | University of Texas Southwestern Medical Center | 2013-02-01 |
| Integrated Supported Employment in Mainland China (NCT03273530) | The Hong Kong Polytechnic University | 2013-02-01 |
| Study of Repetitive Transcranial Magnetic Stimulation in the Treatment of Cognitive Impairment in Schizophrenia (NCT01940939) | Shanghai Mental Health Center | 2013-02-01 |
| SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia (NCT01760889) | Shire | 2013-02-01 |
| Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. (NCT01786369) | Northwell Health | 2013-02-01 |
| Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (NCT01795547) | H. Lundbeck A/S | 2013-02-01 |
| Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis (NCT01876056) | Pakistan Association of Cognitive Therapists | 2013-02-01 |
| Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (NCT01794897) | University of Pittsburgh | 2013-02-01 |
| Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia (NCT02013232) | Beijing HuiLongGuan Hospital | 2013-02-01 |
| Coaching Intervention for Patients With Early Psychosis (NCT01792856) | The University of Hong Kong | 2013-02-01 |